<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04066114</url>
  </required_header>
  <id_info>
    <org_study_id>DAIT CTOT-24</org_study_id>
    <secondary_id>NIAID CRMS ID#: 38581</secondary_id>
    <nct_id>NCT04066114</nct_id>
  </id_info>
  <brief_title>Treg Modulation With CD28 and IL-6 Receptor Antagonists</brief_title>
  <official_title>Regulatory T Cell Modulation in Kidney Transplantation With Biologic Blockade of Dual Effector Pathways, CD28 and IL-6 (CTOT-24)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Trials in Organ Transplantation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of using lulizumab pegol with&#xD;
      tocilizumab, belatacept, and everolimus in kidney transplant recipients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research study is for adults who are planning to have a kidney transplant from a living&#xD;
      donor.&#xD;
&#xD;
      In Brief:&#xD;
&#xD;
      Those who have a transplant take immunosuppressive therapy to prevent the body from rejecting&#xD;
      the transplanted organ. Rejection occurs when the body's defense system (immune cells)&#xD;
      recognizes the transplant as a foreign object. These immune cells and the substances they&#xD;
      produce can damage the transplanted kidney. It is important to prevent rejection episodes, so&#xD;
      the kidney transplant lasts as long as possible.&#xD;
&#xD;
      Most transplant doctors in the United States give a combination of two or three drugs to&#xD;
      prevent rejection. People with a transplant must take these drugs every day. Although kidney&#xD;
      transplant recipients usually do well in the first five years after transplant, researchers&#xD;
      want to find new ways to prevent rejection and avoid the side effects that the current drugs&#xD;
      can cause.&#xD;
&#xD;
      This study will test a new combination of four drugs to evaluate whether this combination is&#xD;
      safe for kidney transplant recipients:&#xD;
&#xD;
        -  lulizumab pegol (BMS-931699)&#xD;
&#xD;
        -  tocilizumab&#xD;
&#xD;
        -  belatacept and&#xD;
&#xD;
        -  everolimus.&#xD;
&#xD;
      Belatacept and everolimus are already approved for use as anti-rejection drugs in kidney&#xD;
      transplant recipients. Lulizumab pegol and tocilizumab act on specific molecules&#xD;
      (specifically CD28 and interleukin 6, respectively) on immune cells: these actions are&#xD;
      different from how the older rejection drugs work.&#xD;
&#xD;
      Summary: This is a prospective multicenter open-label clinical trial of 10 living donor&#xD;
      kidney transplant recipients. Safety of lulizumab pegol (BMS-931699) in the context of a&#xD;
      novel immunosuppressive regimen (anti-thymocyte globulin (rabbit) (ATG), steroids,) Nulojix®&#xD;
      (belatacept), Actemra® (tocilizumab), and Zortress®(everolimus)) will be assessed. Study&#xD;
      participation involves a minimum of one year of follow-up post-transplant.&#xD;
&#xD;
      *** IMPORTANT NOTICE: *** The National Institute of Allergy and Infectious Diseases and the&#xD;
      Clinical Trials in Organ Transplantation (CTOT) do not recommend the discontinuation of&#xD;
      immunosuppressive therapy for recipients of cell, organ, or tissue transplants outside of&#xD;
      physician-directed, controlled clinical studies. Discontinuation of prescribed&#xD;
      immunosuppressive therapy can result in serious health consequences and should only be&#xD;
      performed in certain rare circumstances, upon the recommendation and with the guidance of&#xD;
      your health care provider.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 11, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants who remain free of biopsy-proven acute T-cell mediated or antibody-mediated rejection as defined by Banff criteria</measure>
    <time_frame>6 months post transplantation</time_frame>
    <description>Definitions:&#xD;
Acute T cell Mediated Rejection: Biopsy proven rejection defined by histologic evidence of a Banff grade of ≥1A and clinical treatment for acute rejection.&#xD;
Acute Antibody Mediated Rejection: Diffusely positive immunostaining staining for C4d, presence of circulating anti-donor antibodies, and morphologic evidence of acute tissue injury.&#xD;
Reference: Banff 2007 Classification Renal Allograft Pathology definition of terms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants who remain free of biopsy-proven acute T-cell mediated or antibody-mediated rejection as defined by Banff criteria</measure>
    <time_frame>12 months post transplantation</time_frame>
    <description>Definitions:&#xD;
Acute T cell Mediated Rejection: Biopsy proven rejection defined by histologic evidence of a Banff grade of ≥1A and clinical treatment for acute rejection.&#xD;
Acute Antibody Mediated Rejection: Diffusely positive immunostaining staining for C4d, presence of circulating anti-donor antibodies, and morphologic evidence of acute tissue injury.&#xD;
Reference: Banff 2007 Classification Renal Allograft Pathology definition of terms.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>EXPLORATORY: Frequency of circulating T Regulatory Cells (Tregs)</measure>
    <time_frame>Day 0 (Pre-transplant) and -3, -6 and -12 months post transplantation</time_frame>
    <description>Mechanistic assay. Evaluation of the frequency of circulating Tregs over time.Exploratory goal: To advance understanding in mechanisms of tolerance.</description>
  </other_outcome>
  <other_outcome>
    <measure>EXPLORATORY:T Regulatory Cells (Treg) suppressive activity</measure>
    <time_frame>Day 0 (Pre-transplant) and -3, -6 and -12 months post transplantation</time_frame>
    <description>Mechanistic assay.Donor-specific suppression activity of recipient Tregs will be measured over time by using irradiated donor peripheral blood mononuclear cells (PBMCs) as stimulators. Exploratory goal: To advance understanding in mechanisms of tolerance.</description>
  </other_outcome>
  <other_outcome>
    <measure>EXPLORATORY:Alloreactive T cell frequency</measure>
    <time_frame>Day 0 (Pre-transplant) and -3, -6 and -12 months post transplantation</time_frame>
    <description>Mechanistic assay that measures the frequency of circulating donor-reactive CD4 conventional T cells, CD8 T cells and Tregs analyzed over time. Exploratory goal: To advance understanding in mechanisms of tolerance.</description>
  </other_outcome>
  <other_outcome>
    <measure>EXPLORATORY:Expression of T cell checkpoint inhibition related genes</measure>
    <time_frame>Day 0 (Pre-transplant) and -3, -6 and -12 months post transplantation</time_frame>
    <description>Methodology: Analysis of gene expression in peripheral blood mononuclear cells (PBMCs) stimulated with donor antigen presenting cells to explore genes implicated in T cell checkpoint inhibition (CTLA-4, SFASL, NFATC1, NFATC2, LAG3 and HAVCR2, as examples). Exploratory goal: To advance understanding in mechanisms of tolerance.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Living-Donor Kidney Transplant</condition>
  <condition>Kidney Transplant Recipients</condition>
  <arm_group>
    <arm_group_label>lulizumab pegol + novel ISR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lulizumab pegol + novel ISR: lulizumab pegol plus immunosuppressive regimen (anti-thymocyte globulin (rabbit), steroids,) belatacept, tocilizumab, and everolimus)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>lulizumab pegol</intervention_name>
    <description>25 mg subcutaneously (SC) on Day 1 post transplantation then 12.5 mg SC weekly through day 77 (Week 11)</description>
    <arm_group_label>lulizumab pegol + novel ISR</arm_group_label>
    <other_name>BMS-931699</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>antithymocyte globulin (rabbit)</intervention_name>
    <description>1.5 mg/kg intravenously (IV) on Day 0 (day of transplantation) and the day following (Day 1)</description>
    <arm_group_label>lulizumab pegol + novel ISR</arm_group_label>
    <other_name>ATG (rabbit)</other_name>
    <other_name>Thymoglobulin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
    <description>500 mg (IV) on Day 0 (day of transplantation), 250 mg (IV) on Day 1 and 125 mg (IV) on Day 2</description>
    <arm_group_label>lulizumab pegol + novel ISR</arm_group_label>
    <other_name>Solu-Medrol ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tocilizumab</intervention_name>
    <description>8 mg/kg (IV) on Day 2 post transplantation followed by 162 mg (SC) every 2 weeks through day 168 (Week 24)</description>
    <arm_group_label>lulizumab pegol + novel ISR</arm_group_label>
    <other_name>Actemra®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Beginning on Day 3 post transplantation, taken orally: 60 mg daily&#xD;
Days 4 through 10: 30 mg daily&#xD;
Days 11 through 17: 20 mg daily&#xD;
Days 18 through 24: 10 mg daily&#xD;
After Day 24: continued taper of dose to final maintenance dose of 5 mg, per protocol</description>
    <arm_group_label>lulizumab pegol + novel ISR</arm_group_label>
    <other_name>prednisone tablets</other_name>
    <other_name>Rayos®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>everolimus</intervention_name>
    <description>Initial dose of 0.75 mg taken orally twice daily on Day 14 days after transplantation. Dose will be titrated to target trough levels 3-8 ng/mL.</description>
    <arm_group_label>lulizumab pegol + novel ISR</arm_group_label>
    <other_name>Zortress®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>belatacept</intervention_name>
    <description>5 mg/kg (IV) every 4 weeks starting on Day 84 (Week 12) and continuing through Day 364 (Week 52)</description>
    <arm_group_label>lulizumab pegol + novel ISR</arm_group_label>
    <other_name>Nulojix®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <description>An option for participants who do not tolerate everolimus: to be switched to either&#xD;
mycophenolate mofetil 1000 mg administered orally twice daily or&#xD;
mycophenolic acid</description>
    <arm_group_label>lulizumab pegol + novel ISR</arm_group_label>
    <other_name>MMF</other_name>
    <other_name>CellCept®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolic acid</intervention_name>
    <description>An option for participants who do not tolerate everolimus: to be switched to either&#xD;
mycophenolic acid 720 mg taken orally twice daily or&#xD;
mycophenolate mofetil</description>
    <arm_group_label>lulizumab pegol + novel ISR</arm_group_label>
    <other_name>Myfortic®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Individuals who meet all the following criteria are eligible for enrollment as study&#xD;
        participants:&#xD;
&#xD;
          1. Able to understand and provide informed consent&#xD;
&#xD;
          2. Agreement to use highly effective (&lt;1% failure rate) methods of contraception: Women&#xD;
             of Childbearing Potential (WOCBP)-&#xD;
&#xD;
               -  Progestogen only hormonal contraception associated with inhibition of ovulation,&#xD;
&#xD;
               -  Hormonal methods of contraception including oral contraceptive pills containing a&#xD;
                  combination of estrogen + progesterone, vagina ring, injectables, implants and&#xD;
                  intrauterine devices (IUDs),&#xD;
&#xD;
               -  Non-hormonal IUDs,&#xD;
&#xD;
               -  Bilateral tubal occlusion,&#xD;
&#xD;
               -  Vasectomized partner,&#xD;
&#xD;
               -  Intrauterine hormone-releasing system (IUS), or&#xD;
&#xD;
               -  Complete abstinence.&#xD;
&#xD;
             Note: Female participants of childbearing potential must consult with their physician&#xD;
             and determine the most suitable method(s) from this list to be used for 12 months&#xD;
             while on study drug regimen.&#xD;
&#xD;
             Male Participants-&#xD;
&#xD;
             --Must use a latex or other synthetic condom during any sexual activity with WOCBP&#xD;
             until one month after the last dose of lulizumab (e.g., up to 3.5 months in duration).&#xD;
&#xD;
          3. Recipient of primary, nonhuman leukocyte antigen identical living donor kidney&#xD;
             transplant&#xD;
&#xD;
          4. No donor specific antibodies prior to transplant that are considered to be of clinical&#xD;
             significance by the site investigator&#xD;
&#xD;
          5. Epstein-Barr virus (EBV) positive serology&#xD;
&#xD;
          6. Cytomegalovirus (CMV) positive serology, unless donor-recipient pair are both CMV&#xD;
             negative&#xD;
&#xD;
          7. Negative testing for latent Tuberculosis (TB) infection within 3 months prior to&#xD;
             transplant&#xD;
&#xD;
               -  Testing should be conducted using either a purified protein derivative (PPD) or&#xD;
                  an interferon-gamma release assay blood test for TB (i.e. QuantiFERON®-TB Gold&#xD;
                  in-Tube test or T-SPOT® TB test)&#xD;
&#xD;
               -  Subjects with a positive test for latent TB infection must complete appropriate&#xD;
                  therapy for Latent tuberculosis infection (LTBI). ---A subject is considered&#xD;
                  eligible only if they have a negative test for LTBI within 3 months prior to&#xD;
                  transplant or, they have appropriately completed LTBI therapy prior to&#xD;
                  transplant.&#xD;
&#xD;
             Note: Latent TB infection treatment regimens should be among those endorsed by the CDC&#xD;
             (Division of TB Elimination, 2016).&#xD;
&#xD;
          8. In the absence of contraindication, vaccinations must be up to date for hepatitis B,&#xD;
             influenza, pneumococcal, varicella and herpes zoster, and measles, mumps, and rubella&#xD;
             (MMR)&#xD;
&#xD;
          9. Hepatitis C Virus (HCV) antibody positive subjects with negative HCV by PCR testing&#xD;
             are eligible if they:&#xD;
&#xD;
               -  have spontaneously cleared infection, or&#xD;
&#xD;
               -  are in sustained virologic remission for at least 12 weeks after treatment for&#xD;
                  HCV.&#xD;
&#xD;
         10. Negative SARS-CoV-2 PCR test result performed within 2 weeks of transplant (SARS-CoV-2&#xD;
             is the virus that causes COVID-19)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Individuals who meet any of these criteria are not eligible for enrollment as study&#xD;
        participants-&#xD;
&#xD;
          1. Prisoners or subjects who are compulsorily detained&#xD;
&#xD;
          2. Inability or unwillingness of a participant to give written informed consent or comply&#xD;
             with study protocol&#xD;
&#xD;
          3. Candidate for a multiple solid organ or tissue transplants&#xD;
&#xD;
          4. Prior history of organ or cellular transplantation&#xD;
&#xD;
          5. Known to have idiopathic focal segmental glomerulosclerosis (FSGS) as the underlying&#xD;
             cause of kidney failure (ESRD)&#xD;
&#xD;
          6. Requirement for uninterrupted anticoagulation therapy, including Plavix.&#xD;
&#xD;
          7. Known hypersensitivity to mechanistic target of rapamycin (mTOR) inhibitors or&#xD;
             contraindication to everolimus (including history of wound healing complications)&#xD;
&#xD;
          8. History of severe allergic and/or anaphylactic reactions to humanized or murine&#xD;
             monoclonal antibodies&#xD;
&#xD;
          9. Hypersensitivity to rabbit proteins or rabbit anti-thymocyte Globulin (ATG)&#xD;
&#xD;
         10. Known hypersensitivity to ACTEMRA® (tocilizumab) or lulizumab pegol (BMS-931699)&#xD;
&#xD;
         11. The human immunodeficiency virus (HIV) infected subjects, including those who are well&#xD;
             controlled on antiretrovirals&#xD;
&#xD;
         12. Positive hepatitis B surface antigen (HBSAg), or hepatitis B core antibody (HBcAB)&#xD;
             serology&#xD;
&#xD;
         13. Hepatitis C virus antibody positive (HCV Ab+) subjects who have failed to demonstrate&#xD;
             sustained viral remission for more than 12 weeks after anti-viral treatment&#xD;
&#xD;
         14. Subjects with a previous history of active Tuberculosis (TB)&#xD;
&#xD;
         15. Known active current viral, fungal, mycobacterial or other infections (including, but&#xD;
             not limited to tuberculosis and atypical mycobacterial disease, Hepatitis B and C, and&#xD;
             herpes zoster)&#xD;
&#xD;
         16. Donor or recipient residing in areas where the annual incidence ≥ 21 cases per&#xD;
             100,000) for coccidioidomycosis according to current CDC map:&#xD;
             (https://www.cdc.gov/fungal/diseases/coccidioidomycosis/causes.html)&#xD;
&#xD;
               -  Donors or recipients residing in low risk zones (annual &lt;21 cases per 100,000)&#xD;
                  will not require additional screening&#xD;
&#xD;
         17. History of malignancy except treated basal cell cancer of the skin&#xD;
&#xD;
         18. History of hemolytic-uremic syndrome/ thrombotic thrombocytopenia purpura&#xD;
&#xD;
         19. History of demyelinating disorders (e.g., multiple sclerosis, chronic inflammation&#xD;
             demyelinating polyneuropathy)&#xD;
&#xD;
         20. History of gastrointestinal perforations, active inflammatory bowel disease or&#xD;
             diverticulitis&#xD;
&#xD;
         21. Any previous treatment with alkylating agents such as chlorambucil, or with total&#xD;
             lymphoid irradiation&#xD;
&#xD;
         22. Receipt of a live vaccine within 30 days prior to transplantation.&#xD;
&#xD;
         23. Past or current medical problems or findings from physical examination or laboratory&#xD;
             testing that are not listed above, which, in the opinion of the investigator, may:&#xD;
&#xD;
               -  pose additional risks from participation in the study,&#xD;
&#xD;
               -  may interfere with the participant's ability to comply with study requirements,&#xD;
                  or&#xD;
&#xD;
               -  that may impact the quality or interpretation of the data obtained from the study&#xD;
&#xD;
         24. Severe hyperlipidemia (defined by total cholesterol &gt;350 mg/dL, LDL &gt;190 mg/dL, or&#xD;
             triglycerides &gt;500 mg/dL)&#xD;
&#xD;
         25. Transaminase levels elevated more than 1.5 times the upper limit of normal (ULN)&#xD;
             within 7 days prior to enrollment&#xD;
&#xD;
         26. The absolute neutrophil count (ANC) &lt; 2,000 per mm^3 within 7 days prior to enrollment&#xD;
&#xD;
         27. Platelet count less than 100,000 per mm^3 within 7 days prior to enrollment&#xD;
&#xD;
         28. More than 50% CD8+/ CD28- T-cells in peripheral blood&#xD;
&#xD;
         29. A calculated panel reactive antibody (cPRA) ≥20%, as determined by each participating&#xD;
             site's laboratory&#xD;
&#xD;
         30. Positive pregnancy test in women of child bearing potential, currently breastfeeding,&#xD;
             or planning to become pregnant during the timeframe of the study or follow-up period&#xD;
&#xD;
         31. Participation in any other studies with investigational drugs or regimens in the&#xD;
             preceding year&#xD;
&#xD;
         32. A history of a positive SARS-CoV-2 PCR test result (SARS-CoV-2 is the virus that&#xD;
             causes COVID-19)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Flavio Vincenti, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California San Francisco School of Medicine: Transplantation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sindhu Chandran, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of California San Francisco School of Medicine: Transplantation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama School of Medicine: Transplantation</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Newby</last_name>
      <phone>205-996-2577</phone>
      <email>jnewby@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Clifton E. Kew II, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco School of Medicine: Transplantation</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chun Jung Chen</last_name>
      <phone>415-353-8380</phone>
      <email>chunjung.chen@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Flavio Vincenti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado (UC) Health Transplant Center - Anschutz</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Klaas</last_name>
      <phone>303-724-9081</phone>
      <email>samantha.klaas@cuanschutz.edu</email>
    </contact>
    <investigator>
      <last_name>Scott Davis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital: Transplantation</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Brietigam</last_name>
      <phone>312-694-0259</phone>
      <email>s-brietigam@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>John J. Friedewald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center: Transplantation</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irena Kovacevic, BSN, RN</last_name>
      <phone>402-552-2735</phone>
      <email>irena.kovacevic@unmc.edu</email>
    </contact>
    <investigator>
      <last_name>Roslyn B. Mannon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center: Transplantation</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherri Swan-Nesbit</last_name>
      <phone>919-613-6472</phone>
      <email>sherri.swan@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Allan D. Kirk, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation: Transplantation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dianna Sendrey</last_name>
      <phone>216-444-0486</phone>
      <email>sendred2@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Emilio Poggio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.niaid.nih.gov/</url>
    <description>National Institute of Allergy and Infectious Diseases</description>
  </link>
  <link>
    <url>https://www.niaid.nih.gov/about/dait</url>
    <description>Division of Allergy, Immunology, and Transplantation</description>
  </link>
  <link>
    <url>http://www.ctotstudies.org</url>
    <description>Clinical Trials in Organ Transplantation (CTOT)</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 21, 2019</study_first_submitted>
  <study_first_submitted_qc>August 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2019</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adult living-donor kidney transplant recipients</keyword>
  <keyword>novel immunosuppressive (IS) therapy regimen</keyword>
  <keyword>lulizumab pegol (BMS-931699)</keyword>
  <keyword>CD28 and IL-6 biologic blockade</keyword>
  <keyword>CD28 and IL-6 receptor antagonists</keyword>
  <keyword>T regulatory cells (Treg) modulation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Abatacept</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

